Oculis Holding AG (OCS) Long-Term Deferred Tax (2023 - 2024)
Quarterly Long-Term Deferred Tax rose 590.39% to $342456.6 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $342456.6 through Dec 2024, up 590.39% year-over-year, with the annual reading at $342456.6 for FY2024, 590.39% up from the prior year.
Oculis Holding AG's Long-Term Deferred Tax history spans 2 years, with the latest figure at $342456.6 for Q4 2024.
- Long-Term Deferred Tax came in at $342456.6 for Q4 2024, up from $49603.6 in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $342456.6 in Q4 2024 to a low of $49603.6 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Oculis Holding AG | 24.51 Bn | 24.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 342,456.55 |
| Dec 31, 2023 | 49,603.60 |